February 2025 Penny Stocks To Keep An Eye On
Name
Share Price
Market Cap
Financial Health Rating
QuantaSing Group (NasdaqGM:QSG)
$3.08
$128.29M
★★★★★★
TETRA Technologies (NYSE:TTI)
$3.93
$540.42M
★★★★☆☆
Safe Bulkers (NYSE:SB)
$3.89
$410.67M
★★★★☆☆
BAB (OTCPK:BABB)
$0.8206
$6.54M
★★★★★☆
Golden Growers Cooperative (OTCPK:GGRO.U)
$4.50
$67.38M
★★★★★★
North European Oil Royalty Trust (NYSE:NRT)
$4.41
$41.82M
★★★★★★
Permianville Royalty Trust (NYSE:PVL)
$1.43
$47.52M
★★★★★★
PHX Minerals (NYSE:PHX)
$4.16
$154.05M
★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)
$1.35
$23.41M
★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)
$0.8354
$74.1M
★★★★★☆
Click here to see the full list of 732 stocks from our US Penny Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market cap of approximately $260.09 million.
Operations: The company generates revenue primarily from its biotechnology startup segment, totaling $198.77 million.
Market Cap: $260.09M
Vanda Pharmaceuticals, with a market cap of US$260.09 million, is trading significantly below its estimated fair value and maintains a debt-free balance sheet with short-term assets exceeding liabilities. Despite being unprofitable and experiencing increased losses over five years, it has not diluted shareholders recently. The company reported Q4 2024 revenue of US$53.19 million but faced challenges such as FDA rejection of its tradipitant NDA for gastroparesis treatment, which Vanda disputes legally. Notably, Vanda's innovative ASO therapeutic for Charcot-Marie-Tooth disease highlights potential advancements in precision medicine for rare diseases.
Click here to discover the nuances of Vanda Pharmaceuticals with our detailed analytical financial health report.
Review our growth performance report to gain insights into Vanda Pharmaceuticals' future.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: ATRenew Inc. operates a platform for pre-owned consumer electronics transactions and services in China, with a market cap of approximately $623.33 million.
Operations: The company's revenue is derived from its retail electronics segment, generating CN¥15.35 billion.
Market Cap: $623.33M
ATRenew, with a market cap of US$623.33 million, is unprofitable but has reduced losses by 21.8% annually over the past five years. Its management and board are experienced, boasting tenures of 5.7 and 3.7 years respectively. The company's short-term assets of CN¥4 billion exceed both its short-term liabilities (CN¥1.2 billion) and long-term liabilities (CN¥122.5 million), indicating strong liquidity management despite insufficient data on cash runway sustainability under varying conditions. Debt reduction from 12.3% to 8.5% in five years further strengthens its financial position, while earnings growth is forecasted at a substantial rate of 226%.
Unlock comprehensive insights into our analysis of ATRenew stock in this financial health report.
Evaluate ATRenew's prospects by accessing our earnings growth report.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals with a market cap of $512.77 million.
Operations: The company's revenue is primarily generated from Abbreviated New Drug Applications (ANDA), amounting to $70 million.
Market Cap: $512.77M
Elite Pharmaceuticals, with a market cap of US$512.77 million, is navigating financial challenges despite having short-term assets of US$48 million exceeding both short-term (US$14.7 million) and long-term liabilities (US$39.6 million). The company remains unprofitable but has managed to reduce its losses by 14.5% annually over five years and maintains a cash runway exceeding three years due to positive free cash flow growth. Recent earnings showed revenue of US$52.05 million for the nine months ending December 31, 2024, though net losses reached US$21.31 million compared to a previous net income of US$16.78 million year-over-year.
Click here and access our complete financial health analysis report to understand the dynamics of Elite Pharmaceuticals.
Review our historical performance report to gain insights into Elite Pharmaceuticals' track record.
Access the full spectrum of 732 US Penny Stocks by clicking on this link.
Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Jump on the AI train with fast growing tech companies forging a new era of innovation.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:VNDA NYSE:RERE and OTCPK:ELTP.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Investor Focus Turns to Incoming Retail Earnings, Driving Modest Premarket Action for US Equity Futures
US equity futures were flat ahead of Tuesday's opening bell as earnings from major retailers started Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Stock market today: Dow, S&P 500, Nasdaq mixed as Home Depot leads out big retail earnings
US stocks traded mixed on Tuesday as Home Depot (HD) led out this week's results from retail giants, as Wall Street weighs the odds of interest rate cuts. The Dow Jones Industrial Average (^DJI) edged up 0.1%, while the S&P 500 (^GSPC) fell about 0.2%. The tech-heavy Nasdaq Composite (^IXIC) declined 0.4%, continuing a muted start to the week for the major gauges. A steady march of earnings reports from retail giants began with Home Depot (HD) results before the bell. Its profit slightly fell short of expectations in the second quarter, but sales ticked higher amid signs of an end to the US housing market slump. The home improvement chain's shares slipped after the release, but recovered some ground as investors parsed the results. Target (TGT) will share its earnings on Wednesday, followed by Walmart (WMT) on Thursday. Taken together, the group's results will provide insight into how companies and consumers are faring as Trump's tariffs kick in. Areas of growth or stagnation are also in high focus, as shifts in buying choices can reflect shoppers' financial confidence. Read more: The latest on Trump's tariffs In the tech world, Intel (INTC) stock got a boost after SoftBank said it will take a $2 billion stake in the struggling chipmaker. That news followed shortly after a Bloomberg report that the Trump administration is looking to take a 10% stake in the company. This week, investors are counting down to Friday, when Federal Reserve Chair Jerome Powell will deliver remarks at the Jackson Hole symposium in Wyoming. The event often signals the latest in central bank policymakers' views on interest rates, and Powell's speech could be his last as Fed chair. Clues as to what may come next at the Fed's September policy meeting will be in focus as stubborn inflation and a faltering job market make officials' next move a particularly tricky one. Meanwhile, President Trump continued to press for further Ukraine talks, reportedly asking Russian President Vladimir Putin to meet with Volodymyr Zelensky. European leaders rallied around the Ukrainian president at his meeting with Trump on Monday, but markets hit pause as uncertainty loomed over his country's fate. Stocks mixed at the open US stocks were mixed on Tuesday. The Dow Jones Industrial Average (^DJI) edged up 0.1%, while the S&P 500 (^GSPC) fell about 0.2%. The tech-heavy Nasdaq Composite (^IXIC) declined 0.4%, continuing Wall Street stocks' muted start to the week. Home Depot (HD) led out this week's results from retail giants, with its earnings report Tuesday showing a return to consistent same-store sales growth in the US amid signs that the housing market could begin to recover. In the tech world, Intel (INTC) shares jumped after SoftBank said it's taking a $2 billion stake and the Trump administration reportedly weighed taking its own stake worth up to 10% of the troubled chipmaker. Wall Street is looking ahead to to Fed chair Jerome Powell's highly anticipated speech in Jackson Hole on Friday signaling the central bank's latest views on interest rates, Intel stock jumps 5% as SoftBank takes $2 billion stake in ailing chip company Yahoo Finance's Daniel Howley reports: Read more here. Viking Therapeutics stock plunges on high dropout rate in weight-loss pill trial Viking Therapeutics (VKTX) stock tumbled 35% in premarket trading after a phase 2 trial of its weight-loss pill showed a high patient dropout rate. The GLP-1 obesity treatment showed some promising results: Patients lost 12.2% of body weight after 13 weeks. However, 28% of patients dropped out of the trial before it was completed. Viking's oral obesity drug, VK2735, aims to compete with Eli Lilly's drug, orforglipron, which saw a 12% weight-loss rate after 72 weeks. Eli Lilly shares rose 1.5% in premarket trading. "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range — but over 72-weeks," Mizuho analyst Jared Holz wrote in a note. "A much longer trial, and [therefore] LLY looks far better head-to-head." S&P affirms US credit rating US stock futures were muted after the S&P reiterated its credit rating for the US. The 10-year Treasury yield (^TNX) and 30-year yield (^TYX) fell by about 2 basis points to 4.32% and 4.92%, respectively. Bloomberg reports: Read more here. A suite of retail data is set to decode the resilient consumer American shoppers have kept the engine of the nation's GDP humming along. But it's worth pinpointing where all that resilience is coming from, as Yahoo Finance's Hamza Shaban lays out in today's Morning Brief. Read more here. Medtronic appoints 2 new board members after Elliott takes a stake Shares of medical device maker Medtronic (MDT) fell 3% premarket after the company announced it would add two new independent directors to its board. Veteran med-tech executives John Groetelaars and Bill Jellison were appointed, the company said. The change comes as activist investor Elliott Investment Management has become one of its largest shareholders. Additionally, the board formed two new committees, helmed by CEO Geoff Martha. The Growth Committee will evaluate M&A opportunities, R&D investments, and potential divestitures. The Operating Committee will focus on margin expansion and operational efficiency. Home Depot slightly misses Wall Street's mark in Q2 earnings, reiterates guidance Home Depot (HD) released its second-quarter earnings on Tuesday. The retailer's stock fell about 2% premarket before recovering. Yahoo Finance's senior reporter Brooke DiPalma looks at the latest from the home improvement retailer and how the US housing slump has impacted its bottom line. Read more here. Wall Street sees stock market rotation charting 'healthiest path' to new highs The stock market's record rally is showing early signs of broadening beyond Big Tech as investors rotate into lagging sectors, but strategists warn its durability hinges on earnings and Fed policy. Yahoo Finance's Allie Canal reports: Read more here. Premarket trending tickers: Palo Alto, Nu holdings and Intel Here's a look at some of the top stocks trending in premarket trading: Palo Alto Networks (PANW) shares rose 5% in premarket trading on Tuesday after the Santa Clara cybersecurity firm forecast fiscal 2026 revenue and profit above analysts' estimates, citing growing demand for its AI powered cybersecurity solutions. Digital banking group Nu holdings (NU) stock rose 2% before the bell after Morgan Stanley (MS) analyst Jorge Kuri reiterated a Buy rating on the company and set a price target of $18.00. Intel (INTC) stock rose premarket more than 6% after Softbank Group (9984.T) announced a $2 billion capital injection into the US chipmaker that is currently in the middle of a turnaround effort. Good morning. Here's what's happening today. Economic data: Housing starts (July); Building permits (July) Earnings: Home Depot (HD), XPeng (XPEV), Medtronic (MDT), Amer Sports (AS), Toll Brothers (TOL), La-Z-Boy (LZB) Here are some of the biggest stories you may have missed overnight and early this morning: Signs of a healthier path to new records emerge for stocks Nvidia is working on an H20-beating AI chip for China Trump tariffs get S&P seal of approval Why stocks are looking ripe for a regime shift Intel gets a $2 billion lifeline from SoftBank Trump pushes Putin-Zelensky meeting after talks with both Home Depot to report earnings as Wall Street eyes US sales growth Why Google just boosted its stake in a bitcoin miner Intel gets one new investor... for now With chatter today that the government is nearing taking a 10% stake in Intel, I guess I shouldn't be shocked that the bruised tech giant is hoping to gain some Street cred on its future product roadmap by tapping SoftBank and Masa for cash. Embattled Intel CEO Lip-Bu Tan also gains a Trump friend in Masa. SoftBank will invest $2 billion in Intel at $23 a share. 'Semiconductors are the foundation of every industry. For more than 50 years, Intel has been a trusted leader in innovation. This strategic investment reflects our belief that advanced semiconductor manufacturing and supply will further expand in the United States, with Intel playing a critical role," SoftBank chair and CEO Masayoshi Son said in a statement. Intel CEO Lip-Bu Tan added, "We are very pleased to deepen our relationship with SoftBank, a company that's at the forefront of so many areas of emerging technology and innovation and shares our commitment to advancing U.S. technology and manufacturing leadership. Masa and I have worked closely together for decades, and I appreciate the confidence he has placed in Intel with this investment.' It's still something to see this unfolding at Intel, which has billions in cash and is by no means in a financial death spiral. Given Masa's close ties to the Trump administration, I suspect the government stake announcement could come next. None of this is a good signal on Intel's turnaround, bottom line. A Trump administration spokesperson didn't return my request for comment. Stocks mixed at the open US stocks were mixed on Tuesday. The Dow Jones Industrial Average (^DJI) edged up 0.1%, while the S&P 500 (^GSPC) fell about 0.2%. The tech-heavy Nasdaq Composite (^IXIC) declined 0.4%, continuing Wall Street stocks' muted start to the week. Home Depot (HD) led out this week's results from retail giants, with its earnings report Tuesday showing a return to consistent same-store sales growth in the US amid signs that the housing market could begin to recover. In the tech world, Intel (INTC) shares jumped after SoftBank said it's taking a $2 billion stake and the Trump administration reportedly weighed taking its own stake worth up to 10% of the troubled chipmaker. Wall Street is looking ahead to to Fed chair Jerome Powell's highly anticipated speech in Jackson Hole on Friday signaling the central bank's latest views on interest rates, US stocks were mixed on Tuesday. The Dow Jones Industrial Average (^DJI) edged up 0.1%, while the S&P 500 (^GSPC) fell about 0.2%. The tech-heavy Nasdaq Composite (^IXIC) declined 0.4%, continuing Wall Street stocks' muted start to the week. Home Depot (HD) led out this week's results from retail giants, with its earnings report Tuesday showing a return to consistent same-store sales growth in the US amid signs that the housing market could begin to recover. In the tech world, Intel (INTC) shares jumped after SoftBank said it's taking a $2 billion stake and the Trump administration reportedly weighed taking its own stake worth up to 10% of the troubled chipmaker. Wall Street is looking ahead to to Fed chair Jerome Powell's highly anticipated speech in Jackson Hole on Friday signaling the central bank's latest views on interest rates, Intel stock jumps 5% as SoftBank takes $2 billion stake in ailing chip company Yahoo Finance's Daniel Howley reports: Read more here. Yahoo Finance's Daniel Howley reports: Read more here. Viking Therapeutics stock plunges on high dropout rate in weight-loss pill trial Viking Therapeutics (VKTX) stock tumbled 35% in premarket trading after a phase 2 trial of its weight-loss pill showed a high patient dropout rate. The GLP-1 obesity treatment showed some promising results: Patients lost 12.2% of body weight after 13 weeks. However, 28% of patients dropped out of the trial before it was completed. Viking's oral obesity drug, VK2735, aims to compete with Eli Lilly's drug, orforglipron, which saw a 12% weight-loss rate after 72 weeks. Eli Lilly shares rose 1.5% in premarket trading. "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range — but over 72-weeks," Mizuho analyst Jared Holz wrote in a note. "A much longer trial, and [therefore] LLY looks far better head-to-head." Viking Therapeutics (VKTX) stock tumbled 35% in premarket trading after a phase 2 trial of its weight-loss pill showed a high patient dropout rate. The GLP-1 obesity treatment showed some promising results: Patients lost 12.2% of body weight after 13 weeks. However, 28% of patients dropped out of the trial before it was completed. Viking's oral obesity drug, VK2735, aims to compete with Eli Lilly's drug, orforglipron, which saw a 12% weight-loss rate after 72 weeks. Eli Lilly shares rose 1.5% in premarket trading. "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range — but over 72-weeks," Mizuho analyst Jared Holz wrote in a note. "A much longer trial, and [therefore] LLY looks far better head-to-head." S&P affirms US credit rating US stock futures were muted after the S&P reiterated its credit rating for the US. The 10-year Treasury yield (^TNX) and 30-year yield (^TYX) fell by about 2 basis points to 4.32% and 4.92%, respectively. Bloomberg reports: Read more here. US stock futures were muted after the S&P reiterated its credit rating for the US. The 10-year Treasury yield (^TNX) and 30-year yield (^TYX) fell by about 2 basis points to 4.32% and 4.92%, respectively. Bloomberg reports: Read more here. A suite of retail data is set to decode the resilient consumer American shoppers have kept the engine of the nation's GDP humming along. But it's worth pinpointing where all that resilience is coming from, as Yahoo Finance's Hamza Shaban lays out in today's Morning Brief. Read more here. American shoppers have kept the engine of the nation's GDP humming along. But it's worth pinpointing where all that resilience is coming from, as Yahoo Finance's Hamza Shaban lays out in today's Morning Brief. Read more here. Medtronic appoints 2 new board members after Elliott takes a stake Shares of medical device maker Medtronic (MDT) fell 3% premarket after the company announced it would add two new independent directors to its board. Veteran med-tech executives John Groetelaars and Bill Jellison were appointed, the company said. The change comes as activist investor Elliott Investment Management has become one of its largest shareholders. Additionally, the board formed two new committees, helmed by CEO Geoff Martha. The Growth Committee will evaluate M&A opportunities, R&D investments, and potential divestitures. The Operating Committee will focus on margin expansion and operational efficiency. Shares of medical device maker Medtronic (MDT) fell 3% premarket after the company announced it would add two new independent directors to its board. Veteran med-tech executives John Groetelaars and Bill Jellison were appointed, the company said. The change comes as activist investor Elliott Investment Management has become one of its largest shareholders. Additionally, the board formed two new committees, helmed by CEO Geoff Martha. The Growth Committee will evaluate M&A opportunities, R&D investments, and potential divestitures. The Operating Committee will focus on margin expansion and operational efficiency. Home Depot slightly misses Wall Street's mark in Q2 earnings, reiterates guidance Home Depot (HD) released its second-quarter earnings on Tuesday. The retailer's stock fell about 2% premarket before recovering. Yahoo Finance's senior reporter Brooke DiPalma looks at the latest from the home improvement retailer and how the US housing slump has impacted its bottom line. Read more here. Home Depot (HD) released its second-quarter earnings on Tuesday. The retailer's stock fell about 2% premarket before recovering. Yahoo Finance's senior reporter Brooke DiPalma looks at the latest from the home improvement retailer and how the US housing slump has impacted its bottom line. Read more here. Wall Street sees stock market rotation charting 'healthiest path' to new highs The stock market's record rally is showing early signs of broadening beyond Big Tech as investors rotate into lagging sectors, but strategists warn its durability hinges on earnings and Fed policy. Yahoo Finance's Allie Canal reports: Read more here. The stock market's record rally is showing early signs of broadening beyond Big Tech as investors rotate into lagging sectors, but strategists warn its durability hinges on earnings and Fed policy. Yahoo Finance's Allie Canal reports: Read more here. Premarket trending tickers: Palo Alto, Nu holdings and Intel Here's a look at some of the top stocks trending in premarket trading: Palo Alto Networks (PANW) shares rose 5% in premarket trading on Tuesday after the Santa Clara cybersecurity firm forecast fiscal 2026 revenue and profit above analysts' estimates, citing growing demand for its AI powered cybersecurity solutions. Digital banking group Nu holdings (NU) stock rose 2% before the bell after Morgan Stanley (MS) analyst Jorge Kuri reiterated a Buy rating on the company and set a price target of $18.00. Intel (INTC) stock rose premarket more than 6% after Softbank Group (9984.T) announced a $2 billion capital injection into the US chipmaker that is currently in the middle of a turnaround effort. Here's a look at some of the top stocks trending in premarket trading: Palo Alto Networks (PANW) shares rose 5% in premarket trading on Tuesday after the Santa Clara cybersecurity firm forecast fiscal 2026 revenue and profit above analysts' estimates, citing growing demand for its AI powered cybersecurity solutions. Digital banking group Nu holdings (NU) stock rose 2% before the bell after Morgan Stanley (MS) analyst Jorge Kuri reiterated a Buy rating on the company and set a price target of $18.00. Intel (INTC) stock rose premarket more than 6% after Softbank Group (9984.T) announced a $2 billion capital injection into the US chipmaker that is currently in the middle of a turnaround effort. Good morning. Here's what's happening today. Economic data: Housing starts (July); Building permits (July) Earnings: Home Depot (HD), XPeng (XPEV), Medtronic (MDT), Amer Sports (AS), Toll Brothers (TOL), La-Z-Boy (LZB) Here are some of the biggest stories you may have missed overnight and early this morning: Signs of a healthier path to new records emerge for stocks Nvidia is working on an H20-beating AI chip for China Trump tariffs get S&P seal of approval Why stocks are looking ripe for a regime shift Intel gets a $2 billion lifeline from SoftBank Trump pushes Putin-Zelensky meeting after talks with both Home Depot to report earnings as Wall Street eyes US sales growth Why Google just boosted its stake in a bitcoin miner Economic data: Housing starts (July); Building permits (July) Earnings: Home Depot (HD), XPeng (XPEV), Medtronic (MDT), Amer Sports (AS), Toll Brothers (TOL), La-Z-Boy (LZB) Here are some of the biggest stories you may have missed overnight and early this morning: Signs of a healthier path to new records emerge for stocks Nvidia is working on an H20-beating AI chip for China Trump tariffs get S&P seal of approval Why stocks are looking ripe for a regime shift Intel gets a $2 billion lifeline from SoftBank Trump pushes Putin-Zelensky meeting after talks with both Home Depot to report earnings as Wall Street eyes US sales growth Why Google just boosted its stake in a bitcoin miner Intel gets one new investor... for now With chatter today that the government is nearing taking a 10% stake in Intel, I guess I shouldn't be shocked that the bruised tech giant is hoping to gain some Street cred on its future product roadmap by tapping SoftBank and Masa for cash. Embattled Intel CEO Lip-Bu Tan also gains a Trump friend in Masa. SoftBank will invest $2 billion in Intel at $23 a share. 'Semiconductors are the foundation of every industry. For more than 50 years, Intel has been a trusted leader in innovation. This strategic investment reflects our belief that advanced semiconductor manufacturing and supply will further expand in the United States, with Intel playing a critical role," SoftBank chair and CEO Masayoshi Son said in a statement. Intel CEO Lip-Bu Tan added, "We are very pleased to deepen our relationship with SoftBank, a company that's at the forefront of so many areas of emerging technology and innovation and shares our commitment to advancing U.S. technology and manufacturing leadership. Masa and I have worked closely together for decades, and I appreciate the confidence he has placed in Intel with this investment.' It's still something to see this unfolding at Intel, which has billions in cash and is by no means in a financial death spiral. Given Masa's close ties to the Trump administration, I suspect the government stake announcement could come next. None of this is a good signal on Intel's turnaround, bottom line. A Trump administration spokesperson didn't return my request for comment. With chatter today that the government is nearing taking a 10% stake in Intel, I guess I shouldn't be shocked that the bruised tech giant is hoping to gain some Street cred on its future product roadmap by tapping SoftBank and Masa for cash. Embattled Intel CEO Lip-Bu Tan also gains a Trump friend in Masa. SoftBank will invest $2 billion in Intel at $23 a share. 'Semiconductors are the foundation of every industry. For more than 50 years, Intel has been a trusted leader in innovation. This strategic investment reflects our belief that advanced semiconductor manufacturing and supply will further expand in the United States, with Intel playing a critical role," SoftBank chair and CEO Masayoshi Son said in a statement. Intel CEO Lip-Bu Tan added, "We are very pleased to deepen our relationship with SoftBank, a company that's at the forefront of so many areas of emerging technology and innovation and shares our commitment to advancing U.S. technology and manufacturing leadership. Masa and I have worked closely together for decades, and I appreciate the confidence he has placed in Intel with this investment.' It's still something to see this unfolding at Intel, which has billions in cash and is by no means in a financial death spiral. Given Masa's close ties to the Trump administration, I suspect the government stake announcement could come next. None of this is a good signal on Intel's turnaround, bottom line. A Trump administration spokesperson didn't return my request for comment. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
PAR Technology (PAR): High Expected Value, Uncertain Timing
Greenhaven Road Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. A copy of the letter can be downloaded here. In the second quarter, the fund returned approximately +14% net of fees and expenses, bringing the YTD returns to under +1%. YTD, the Russell 2000 has returned -1.8%. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second-quarter 2025 investor letter, Greenhaven Road Capital highlighted stocks such as PAR Technology Corporation (NYSE:PAR). PAR Technology Corporation (NYSE:PAR) offers omnichannel cloud-based hardware and software solutions to the restaurant and retail industries. The one-month return of PAR Technology Corporation (NYSE:PAR) was -25.90%, and its shares lost 1.82% of their value over the last 52 weeks. On August 18, 2025, PAR Technology Corporation (NYSE:PAR) stock closed at $52.25 per share, with a market capitalization of $2.12 billion. Greenhaven Road Capital stated the following regarding PAR Technology Corporation (NYSE:PAR) in its second quarter 2025 investor letter: "PAR Technology Corporation (NYSE:PAR) – PAR is another difficult company to forecast earnings precisely. The company primarily adds new customers through RFP processes, the duration and outcome of which are not known. Even after winning an RFP, the implementation timeline is dictated by the customer. This past quarter saw a rollout implementation slowdown from Burger King, their largest customer, which halted implementation because they are adopting an additional module. This is a very 'good' problem to have – your largest customer slowing down to buy more product. It is also worth noting that Burger King has several additional cross-sale opportunities including Popeye's, Tim Hortons, and Burger King International. Burger King buying more is an excellent data point even if it had a negative impact on last quarter's revenue. An engineer working in a tech lab, surrounded by tools and components. PAR Technology Corporation (NYSE:PAR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 28 hedge fund portfolios held PAR Technology Corporation (NYSE:PAR) at the end of the first quarter compared to 33 in the third quarter. PAR Technology Corporation's (NYSE:PAR) second quarter revenue increased nearly 44% to $112.4 million. While we acknowledge the potential of PAR Technology Corporation (NYSE:PAR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered PAR Technology Corporation (NYSE:PAR) and shared Laughing Water Capital's views on the company in the previous quarter. In its Q1 2025 investor letter, Greenhaven Road Capital highlighted PAR Technology Corporation (NYSE:PAR) as a resilient high growth company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
